A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial)
Masayuki Takeda(Kindai University), Mototsugu Shimokawa(Yamaguchi University), Shigeki Umemura(National Cancer Center Hospital East), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Eiji Iwama(Kyushu University), Takeshi Masuda(Ulvac (Japan)), Takayuki Takahama(Kindai University), Shunichi Sugawara(Sendai Kousei Hospital), Hiroshi Tanaka(Sapporo City General Hospital), Masahide Ota(Nara Medical University), Masahide Oki(Nagoya Medical Center), Takehito Shukuya(Juntendo University)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k